IP Library Patent Application 18939295
Patent Application
App. No. 18/939,295

DEVICES AND METHODS FOR DELIVERY OF PHARMACEUTICAL COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/939,295
Abstract

Described herein are devices for delivering pharmaceutical compositions to individuals in need thereof. Also described herein are methods of using the devices described herein to deliver pharmaceutical compositions to individuals in need thereof.

Claims (22)

1 . An intranasal delivery device for treating an opioid overdose comprising:

a nasal applicator comprising a shaft and an applicator tip coupled to the shaft; and

an absorbent swab material coupled to the applicator tip, wherein,

the absorbent swab material holds from 50 μL to 450 μL of an aqueous naloxone-containing formulation, wherein,

the naloxone-containing formulation has:

a naloxone HCl concentration of at least 45 mg/mL; and

a pH from 3.5 to 5.5; and

from 1 mg to 20 mg of naloxone HCl;

the absorbent swab material is configured to hold the naloxone-containing formulation and to release the naloxone-containing formulation when pressed against the nasal mucosa;

the nasal applicator is configured to contact the absorbent swab material to the nasal mucosa between from 1.5 cm to 3.0 cm from an opening of the nasal passage; and

the applicator tip does not comprise an injection mechanism.

2 . The intranasal delivery device of claim 1 , wherein the naloxone-containing formulation has a naloxone HCl concentration from 45 mg/mL to 90 mg/mL.

3 . The intranasal delivery device of claim 1 , wherein the naloxone-containing formulation comprises a stabilizing agent, a tonicity agent, a chelating agent, a preservative, or a combination of any of the foregoing.

4 . The intranasal delivery device of claim 1 , wherein

The absorbent swab material holds from 100 μL to 300 μL of the naloxone-containing formulation; and

the naloxone-HCl concentration is from 45 mg/mL to 90 mg/mL.

5 . A package comprising the intranasal delivery device of claim 1 .

6 . The package of claim 5 , wherein the package comprises a thermoformed package.

7 . The package of claim 5 , wherein the package comprises a cover encapsulating the intranasal delivery device.

8 . The package of claim 7 , wherein the cover comprises a plastic pack, a plastic pouch, or a foil.

9 . The package of claim 5 , wherein the package comprises a seal.

10 . The package of claim 9 , wherein the seal comprises a hermetic seal.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2026
From: PINOVA THERAPEUTICS INC.
To: FORHUMANITY HEALTH INC.
Reel/Frame 075940/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2025
From: POCKET NALOXONE CORP.
To: PINOVA THERAPEUTICS INC.
Reel/Frame 072058/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2024
From: MATHAI, ASHANTHI
To: POCKET NALOXONE CORP.
Reel/Frame 069160/0990 →